Multiple Myeloma - Healing Genes

Multiple Myeloma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma

Phase 2


University of Arkansas for Medical Science is recruiting participants to trial a drug for relapsed multiple myeloma (MM). The investigational drug utilizes the measles vaccine, a weakened virus which may restore a missing gene to MM tumor cells to make them more susceptible to the immune system and chemotherapy. This missing gene is known to be a problem in many cancers, and previous studies have shown the measles virus to help improve MM.

Participants will be given 1 dose of the investigatory drug via IV, along with a course of chemotherapy, then will be followed for a year.


  • Be 18 to 75 years of age
  • Meet cancer screening requirements specific to the study and MM
  • ≥2 months must have elapsed after the last peripheral blood stem cell transplant prior to enrollment
  • Not be HIV-positive


  1. Screening before the treatment.
  2. A single injection of the vaccine therapy drug will be administered along with a 4-day course of chemotherapy.
  3. Monitoring of the patient during treatment, then follow up for 1 year.


The study location is at the University of Arkansas for Medical Science. Map.


Contact: Brittany Lehman  |  (501) 686-8274  |  [email protected]




University of Arkansas


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader